Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals has agreed to offer commercial-scale manufacturing capabilities for reaZin to Florida-based pharmaceutical preparation manufacturing company TG United.
Subscribe to our email newsletter
Adeona is developing reaZin, a product candidate for the dietary management of Alzheimer’s disease and mild cognitive impairment, as a prescription medical food.
reaZin, formerly named Zinthionein, is a proprietary, gastroretentive, sustained release, once-daily oral tablet formulated from zinc (150 mg) and cysteine (100 mg), an amino acid with potent anti-oxidant properties.
reaZin demonstrated increased serum zinc and decreased serum free copper when administered in patients.
In addition, the average cognitive function of the placebo group declined over 6 months in comparison to patients managed with reaZin.
Adeona CEO James Kuo said executing this agreement for the manufacturing of the product candidate, reaZin, is an important step for commercialization.